# US 10,870,697 B2 · Treatment of fibrosis with interleukin-11 antibody

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,870,697 B2
- Document ID: US10870697B2
- Status: Granted
- Kind: B2
- Application number: 16/055,251
- Filed: 2018-08-06
- Published: 2018-12-20
- Granted: 2020-12-22
- Earliest claimed: 2015-12-16
- Assignees: Singapore Health Services Pte Ltd; National University of Singapore
- Applicants: Singapore Health Services PTE LTD.; National University of Singapore
- Inventors: Stuart Alexander Cook; Sebastian Schaefer
- Web page: https://patentgrep.com/patent/US10870697B2

## CPC

- C07K 16/244: {Interleukins [IL]}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 13/12: of the kidneys
- A61P 27/02: Ophthalmic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/5428: {IL-10}
- C07K 14/7155: {for interleukins [IL]}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C12N 15/1136: {against growth factors, growth regulators, cytokines, lymphokines or hormones}
- C12N 15/1138: {against receptors or cell surface proteins}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- C07K 2317/20: characterized by taxonomic origin
- C07K 2317/21: from primates, e.g. man
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2319/00: Fusion polypeptide
- C07K 2319/32: fusions with soluble part of a cell surface receptor, "decoy receptors"
- C07K 2319/43: containing a FLAG-tag
- C12N 2310/14: interfering nucleic acids [NA]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

## Claims

### Claim 1

A method of treating a disease or condition characterised by fibrosis of an organ of the respiratory system in a human subject, the method comprising administering to the human subject in need of treatment a therapeutically effective amount of an Interleukin 11 (IL-11) antibody which is capable of inhibiting IL-11 mediated signaling.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the disease or condition is characterised by fibrosis of the lung.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the disease or condition is selected from the group consisting of pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), cystic fibrosis, idiopathic pulmonary fibrosis, progressive massive fibrosis, scleroderma, obliterative bronchiolitis, Hermansky-Pudlak syndrome, asbestosis, silicosis, chronic pulmonary hypertension, AIDS associated pulmonary hypertension, sarcoidosis, tumor stroma in lung disease and asthma.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the antibody is capable of inhibiting or reducing the binding of IL-11 to an IL-11 receptor.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the method comprises administering said antibody to a subject in which IL-11 or IL-11R expression is upregulated.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the method comprises administering said antibody to a subject in which IL-11 or IL-11R expression has been determined to be upregulated.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the method comprises determining whether IL-11 or IL-11R expression is upregulated in the subject and administering said antibody to a subject in which IL-11 or IL-11R expression is upregulated.

### Claim 8

A method of treating a disease or condition characterised by fibrosis of the respiratory system selected from the group consisting of: pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), cystic fibrosis, idiopathic pulmonary fibrosis, progressive massive fibrosis, scleroderma, obliterative bronchiolitis, Hermansky-Pudlak syndrome, asbestosis, silicosis, chronic pulmonary hypertension, AIDS associated pulmonary hypertension, sarcoidosis, tumor stroma in lung disease and asthma in a human subject, the method comprising administering to the human subject in need of treatment a therapeutically effective amount of an Interleukin 11 (IL-11) antibody which is capable of inhibiting IL-11 mediated signaling.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the antibody is capable of inhibiting or reducing the binding of IL-11 to an IL-11 receptor.

### Claim 10 (depends on 8)

The method according to claim 8, wherein the method comprises administering said antibody to a subject in which IL-11 or IL-11R expression is upregulated.

### Claim 11 (depends on 8)

The method according to claim 8, wherein the method comprises administering said antibody to a subject in which IL-11 or IL-11R expression has been determined to be upregulated.

### Claim 12 (depends on 8)

The method according to claim 8, wherein the method comprises determining whether IL-11 or IL-11R expression is upregulated in the subject and administering said antibody to a subject in which IL-11 or IL-11R expression is upregulated.